Insulet (NSDQ:PODD) said today that it has assumed direct commercial operations in Europe for its Omnipod tubeless insulin pump.
The Billerica, Mass.-based company first announced it would part ways with its former European distributor, Ypsomed, in July last year. Insulet has since established a team of more than 100 employees to take care of distributing and selling its Omnipod system in Europe, the company reported.
“We are thrilled to directly support the diabetes community across Europe now and into the future,” chairman & CEO Patrick Sullivan said in prepared remarks. “We have a very accomplished team in place whose sole focus is to deliver an exceptional customer experience and we are deeply committed to bringing customized innovation to the local European markets.”
“Insulet has always been committed to putting the patient first and direct operations in Europe is a big step forward for all Omnipod users,” Eric Renard, an endocrinology professor at Lapeyronie University Hospital, added. “Insulet is making a significant, long-term commitment to the diabetes community in Europe and I’m excited they plan to bring new innovations to market that best serve the local European customers.”
The company’s diabetes technologies continue to make progress in the U.S., as well. Last month, Insulet won 510(k) clearance from the FDA for its Omnipod Dash insulin management system that wirelessly connects the company’s Personal Diabetes Manager with the Omnipod pump.
The PDM calculates how much insulin should be administered using blood glucose readings from the Contour Next One blood glucose meter. Altogether, the system connects via Bluetooth to the Omnipod Display and Omnipod View apps, which provide users and caregivers with access to their insulin therapy data.
